Last reviewed · How we verify
Cancer Trials Ireland — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
4 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dexamethasone (IV) | Dexamethasone (IV) | marketed | Glucocorticoid (corticosteroid) | Glucocorticoid receptor (GR) | Oncology, Immunology, Inflammation | |
| Cisplatin / Oxaliplatin | Cisplatin / Oxaliplatin | phase 3 | Platinum-based chemotherapy agent | DNA | Oncology |
Therapeutic area mix
- Oncology · 2
- Oncology, Immunology, Inflammation · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Merck Sharp & Dohme LLC · 2 shared drug classes
- Biocad · 1 shared drug class
- Federation Francophone de Cancerologie Digestive · 1 shared drug class
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
- Chinese Academy of Medical Sciences · 1 shared drug class
- Celgene · 1 shared drug class
- Amgen · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Cancer Trials Ireland:
- Cancer Trials Ireland pipeline updates — RSS
- Cancer Trials Ireland pipeline updates — Atom
- Cancer Trials Ireland pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cancer Trials Ireland — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cancer-trials-ireland. Accessed 2026-05-16.